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Granzymes  are  serine  proteases  involved  in killing  of  tumor  cells  and  virally  infected  cells.  However,
granzymes  are  also  upregulated  in  blood  under  inﬂammatory  conditions  and  contribute  to  cytokine
release  and  processing.  Here,  we  show  that  granzyme  M (GrM)  and  to  a lesser  extent  GrK are transiently
elevated  in the  circulation  following  LPS  administration  in  humans.  GrM is  released  upon  stimulation  of
whole  blood  with  LPS or the  gram-negative  bacteria  Escherichia  coli  BL21,  Pseudomonas  aeruginosa,  andeywords:
ranzyme K
ranzyme M
ipopolysaccharide (LPS)
nﬂammation
Neisseria  meningitidis.  GrK  is only  released  upon  stimulation  with  P. aeruginosa.  Thus,  GrM  and  GrK  are
differentially  released  in  response  to  LPS  and  gram-negative  bacteria.
©  2016  Elsevier  GmbH.  All  rights  reserved.ndotoxemia
. Introduction
Severe sepsis is a major health problem, resulting in a signiﬁ-
ant number of deaths each year (Angus and van der Poll, 2013).
he disease is caused by a local microbial infection that spreads to
he circulation, resulting in a systemic inﬂammatory disorder that
an cause irreversible organ injury and may  ultimately result in
eath (Angus and van der Poll, 2013). Although mortality rates of
epsis have dropped over the past decades due to improved hospi-
al care of patients, 20–30% of patients with severe sepsis still die,
nd effective treatment options are lacking (Angus and van der Poll,
013).
Granzymes are a set of homologous serine proteases expressed
n cytotoxic lymphocytes and are involved in the killing of tumor
ells and virally infected cells (Bovenschen and Kummer, 2010). In
umans, there are ﬁve granzymes: granzyme A (GrA), GrB, GrH,
rK, and GrM. Following target cell recognition by cytotoxic lym-
hocytes, granzymes are directed inside the target cell where they
an activate pro-apoptotic pathways by cleavage of various sub-
∗ Corresponding author at: Department of Pathology, University Medi-
al  Center Utrecht Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.
ax:  +31 30 2544990.
E-mail address: n.bovenschen@umcutrecht.nl (N. Bovenschen).
ttp://dx.doi.org/10.1016/j.imbio.2016.02.006
171-2985/© 2016 Elsevier GmbH. All rights reserved.strates, resulting in apoptosis (Bovenschen and Kummer, 2010;
Chowdhury and Lieberman, 2008).
In addition to their cytotoxic potential, granzymes also play
a role in inﬂammation. Levels of soluble granzymes A, B, K, and
M are elevated in the circulation under inﬂammatory conditions,
including endotoxemia and sepsis (Wensink et al., 2014; Lauw
et al., 2000; Zeerleder et al., 2005; Hollestelle et al., 2011; Rucevic
et al., 2007; Buzza and Bird, 2006). GrM and GrA knockout mice
survive longer than wild-type (WT) mice, in response to a nor-
mally lethal LPS challenge (Anthony et al., 2010; Metkar et al.,
2008), and GrM−/− mice express lower levels of cytokines than
WT mice upon LPS challenge (Anthony et al., 2010). In addition,
we have recently demonstrated that GrK synergistically potenti-
ates cytokine responses from human monocytes induced by LPS or
gram-negative bacteria (Wensink et al., 2014). This suggests that
granzymes are involved in the (innate) immune response against
bacterial infections.
Soluble GrA and GrB are released in serum during experimen-
tal human endotoxemia and following stimulation of whole blood
with LPS and bacteria (Lauw et al., 2000). However, it remains
unknown whether GrK and GrM are also secreted in response to
stimulation with LPS or bacteria. Here, we report that injection of
LPS into healthy volunteers triggers a temporary increase in solu-
ble GrM and, to a lesser extent, GrK levels. Whole blood stimulation
with LPS or three strains of gram-negative bacteria results in GrM
release, whereas GrK release is more restricted and is observed only
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pon stimulation with the gram-negative bacterium Pseudomonas
eruginosa, but not with Escherichia coli BL21, Neisseria meningitidis,
r LPS.
. Materials and methods
.1. Experimental human endotoxemia
Five healthy nonsmoking male volunteers (mean age: 24.4
ears, range: 21–30 years) were admitted to the Clinical Research
nit of the Academic Medical Center, Amsterdam. Physical and
outine laboratory examination were normal, as well as medical
istory and electrocardiography. Each volunteer was  given a bolus
ntravenous (i.v.) injection of 4 ng/kg LPS (E. coli O113, CC-RE lot 3,
ational Institutes of Health, USA), administered over 1 min  in an
ntecubital vein. Blood was collected in EDTA tubes immediately
efore injection, and furthermore at time points 0.5, 1, 1.5, 2, 3, 4,
, 6, 8, 12, and 20 h post injection. After centrifugation, plasma was
ransferred to clean vials and stored at −80 ◦C until analysis. The
linical response of the volunteers to the LPS injection, as well as
heir leukocyte and lymphocyte counts, were similar to previously
ublished results (Lauw et al., 2000). The study was approved of
y the Medical Ethics Commission of the AMC, Amsterdam, The
etherlands, and written informed consent was obtained from all
ubjects.
.2. Whole blood stimulation with LPS or gram-negative bacteria
Whole blood from healthy volunteers (other than described
n the previous paragraph) was collected in sodium heparin
acutainers (Becton Dickinson). Blood was diluted in serum-free
PMI 1640 to a ﬁnal dilution of 1:5 (blood:RPMI). LPS (E. coli
111:B4) (0–50 ng/ml) was added and samples were incubated for
–24 h under standard incubator conditions (37 ◦C, 5% CO2, rel-
tive humidity (RH) 95%). After incubation, blood was collected
nd centrifuged at 4 ◦C for 5 min  at 500 g. Plasma supernatants
ere transferred to clean eppendorf tubes and stored at −20 ◦C
ntil analysis. Alternatively, whole blood was stimulated with
ive gram-negative bacteria added in a 2-fold excess compared to
BMC numbers (∼1 × 10E6 PBMCs/ml in whole undiluted blood).
scherischia coli BL21 (E.coli BL21), P. aeruginosa 01 (PA-01), or
eisseria meningitides HB-1 (NM) were used. All bacterial strains
ere a kind gift from the Medical Microbiology Department (UMC,
trecht). Bacteria were grown overnight on TSASB plates at 37 ◦C,
xcept for N. meningitidis, which was grown on GB-Choco plates
37 ◦C, 5% CO2, RH 95%). Bacteria were diluted in PBS to OD ∼0.5 at
60 nm (representing approximately 5 × 10E8 bacteria/ml), and
dded in the correct concentration to whole blood pre-diluted as
escribed above. After incubation, plasma samples were obtained
s described above.
.3. Granzyme and cytokine measurements in plasma and serum
amples
GrM and GrK levels in samples were determined using ELISA
Uscn Life Science Inc., lower detection limit for both assays
3 pg/ml). The speciﬁcity of the ELISAs was conﬁrmed using West-
rn Blot for GrM and GrK (data not shown). TNF and IL6 were
easured in EDTA anticoagulated plasma by Luminex multiplex
ssay using BioPlex 200 (BioRad, Hercules, CA).
.4. Granzyme M FACS stainingPBMCs were isolated from healthy volunteers using Ficoll den-
ity gradient. Cells were cultured in RPMI 1640 supplemented with
0% FCS, 2 mM l-glutamine, 100 U/ml penicillin and 100 g/mllogy 221 (2016) 773–777
streptomycin. Cells (5 × 10E5) were treated with or without
20 ng/ml LPS for 18 h. Cells were incubated with one of two  cell-
surface marker combinations prior to determine GrM protein levels
in different cell subsets: (1) CD3-Paciﬁc Blue (Biolegend), CD8-
PerCP, CD56-PE-Cy7, CD14-V500 (BD), CD16-APC (eBioscience);
(2) CD3-Paciﬁc Blue, CD4-PE-Cy7 (Biolegend), CD8-PerCP (BD).
Cells were subsequently permeabilized for intracellular GrM stain-
ing. After ﬁxation and permeabilization, cells were incubated
with Alexa Fluor 488-conjugated anti-GrM (clone 4B2G4) as we
described previously (Bovenschen et al., 2014; de Koning et al.,
2010). Samples were measured at FACS Canto II and analyzed using
FACSdiva software. The monocytes were identiﬁed based on char-
acteristic properties of the cells in the forward (FSC) and side scatter
(SSC) and then divided in CD14+ and CD16+ monocytes. Within the
lymphocyte gate based on FSC/SSC, the T cells were gated on CD3+
and then divided in CD4+ or CD8+. NK cells were gated as CD3-
CD16 + CD56+. NKT cells are gated as CD3 + CD56+. Within these
populations, the percentage of GrM+ cells was  deﬁned.
3. Results
3.1. GrM and GrK are released in human experimental
endotoxemia
Human endotoxemia was  modeled by injecting ﬁve healthy vol-
unteers with LPS intravenously. Serum was collected at different
time points post LPS injection, and granzymes were measured. Both
GrK and GrM serum levels showed a temporary rise upon LPS injec-
tion (Fig. 1a and b). A major peak in GrM levels was  observed
after ∼2 h, with a minor peak following after ∼5–8 h (Fig. 1a).
A less clear but recognizable rise in GrK levels was observed in
several donors (Fig. 1b). When GrK and GrM levels in individ-
ual volunteers are compared, peaks in GrK and GrM levels largely
coincided (Fig. 1c–g). As expected, TNF (Fig. 1h) and IL6 (Fig. 1i)
levels in serum transiently increase following LPS injection, with
peak levels that coincide with the peak levels of serum granzymes.
However, there is no correlation between the absolute responses
of granzymes and proinﬂammatory cytokines to LPS (at least in
these 5 patients), suggesting that the different granzyme responses
among individuals cannot be explained by different responses to
LPS. These data indicate that GrM and to a lesser extent GrK are
released in human experimental endotoxemia.
3.2. GrM, but not GrK, is released in LPS-treated whole blood
cultures
We  next addressed whether LPS can trigger GrK and GrM release
in whole blood. Incubation of whole blood with LPS induced a
clear time-dependent increase in soluble GrM levels (Fig. 2a),
observed in four out of ﬁve donors. In contrast, no GrK release
was observed under the same circumstances in four out of ﬁve
donors tested (Fig. 2b). In one donor, minor amounts of GrK were
released (∼30 pg/ml after 24 h incubation with 50 ng/ml LPS). No
granzyme was detected without incubation or after incubation
of untreated blood (Fig. 2a and b). Subsequently, we measured
intracellular GrM expression in several PBMC subsets of four inde-
pendent donors upon LPS treatment. The amount of GrM-positive
cells did not change in NK cell, NKT cell, CD8+ T cell, CD4+ T
cell, and CD14+ monocyte subsets (Fig. 2c). Surprisingly, however,
CD16+ monocytes did express GrM (unstimulated), and this GrM
expression increased following LPS treatment (in three out of four
donors). Taken together, these data indicate that GrM, but not GrK,
is released in response to LPS stimulation.
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rig. 1. GrM and GrK are released in human experimental endotoxemia.
ive male subjects were injected intravenously with LPS at t = 0 and blood was  dra
evels  using ELISA. The course of circulating GrK and GrM (c-g), and TNF (h) and IL.3. GrM and GrK are differentially released in whole blood
reated with gram-negative bacteria
LPS is an important cell wall constituent of gram-negative bacte-
ia. Therefore, GrK and GrM release in whole blood upon incubationt different time points after injection. Sera were analyzed for GrM (a) and GrK (b)
evels in each volunteer is depicted in ﬁgures (volunteer 1–5, respectively).with gram-negative bacteria was  investigated. Whole blood was
stimulated with E. coli BL21, P. aeruginosa (PA-01), or N. menin-
gitidis (NM), added in a 2-fold excess compared to peripheral
blood mononuclear cell (PBMC) numbers. All three bacterial species
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Fig. 2. GrM and GrK release in whole blood stimulated with LPS or gram-negative bacteria.
(a, b) GrM, but not GrK, is released in whole blood upon LPS stimulation. Whole blood, diluted 1:5 (blood:medium), was incubated with LPS (0–50 ng per ml). At different
time  points GrM (a) and GrK (b) levels in culture supernatant were determined using ELISA. Data are representative of ﬁve independent experiments. (c) Isolated PBMCs (four
independent donors) were treated with LPS (20 ng/ml) (closed symbols) or without LPS (open symbols) for 18 h. Indicated cell subsets were FACS stained for intracellular
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L21  (E. coli BL21), Pseudomonas aeruginosa 01 (PA-01), or Neisseria meningitidis HB
rM  (d) and GrK (e) levels in the culture supernatant were determined. Data are re
aused a marked GrM release at 6 h and 24 h following incubation
Fig. 2d). Interestingly, GrK was only released upon treatment with
A-01, and only after 24 h of incubation (Fig. 2e). Soluble GrK or
 were not released in blood incubated without bacteria (Fig. 2d
nd e). These data demonstrate that GrM and GrK are differen-
ially released in whole blood upon incubation with gram-negative
acteria.
. Discussion
It is well established that granzymes A, B, K, and M are elevated
n the blood circulation during endotoxemia and sepsis (Wensink
t al., 2014; Lauw et al., 2000; Zeerleder et al., 2005; Hollestelle
t al., 2011; Rucevic et al., 2007; Buzza and Bird, 2006). Evidence
s emerging that these extracellular granzymes play a role during
he process of inﬂammation, for instance via induction of pro-
nﬂammatory cytokine responses (Wensink et al., 2014; Metkar
t al., 2008). Like for GrA and GrB (Lauw et al., 2000), we reportia. Whole blood, ﬁnal dilution 1:5 (blood:medium), was treated with Escherichia coli
M) added in two-fold excess compared to PBMC numbers. At different time points
tative of three (PA-01) or two (E. coli BL21 and NM)  independent experiments.
here that GrM and GrK are secreted during human experimental
endotoxemia and in whole blood cultures stimulated with LPS or
gram-negative bacteria (Figs. 1 and 2). In healthy volunteers, a tran-
sient rise in GrM levels was  observed (Figs. 1 and 2), accompanied
by a modest temporary rise in GrK levels (Fig. 1). These results
agree with reports demonstrating that GrM and GrK are elevated
in the circulation during sepsis (Wensink et al., 2014; Hollestelle
et al., 2011; Rucevic et al., 2007). In whole blood cultures, GrM
was released upon stimulation with LPS or gram-negative bacte-
ria, and remained high for at least 24 h (Fig. 2). GrK was released
upon treatment with the gram-negative bacterium P. aeruginosa,
but not in response to E. coli BL21, N. meningitidis, or LPS (E. coli
0111:B4) (Fig. 2). Thus, in vitro granzyme release induced by LPS
or gram-negative bacteria depends on the bacterial type and seems
more restricted for GrK than for GrM, at least for the bacteria tested
in this study.
Except for one donor, GrM levels in healthy volunteers were
undetectable before LPS injection (Fig. 1), consistent with GrM
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Zeerleder, S., Hack, C.E., Caliezi, C., van Mierlo, G., Eerenberg-Belmer, A., Wolbink,
A., Wuillenmin, W.A., 2005. Activated cytotoxic T cells and NK cells in severe
sepsis and septic shock and their role in multiple organ dysfunction. Clin.
Immunol. 116, 158–165.A.C. Wensink et al. / Immu
aseline levels detected in blood plasma in vitro (Fig. 2). In contrast,
oluble GrK is clearly detectable in serum of healthy volunteers
t the start of the measurements (Fig. 1). This ﬁnding is in agree-
ent with results published by us and others (Wensink et al., 2014;
ucevic et al., 2007; Bade et al., 2005), but differs from the low GrK
evels we found in plasma in the absence of stimulation in vitro
Fig. 2). Thus, basal circulating GrK and to a lesser extent GrM levels
ary amongst individuals.
It remains unknown from which cell type(s) GrM and GrK are
eleased upon stimulation with LPS or bacteria. Candidates include
K cells, as they store large amounts of GrM and GrK (Bovenschen
nd Kummer, 2010). NK cells respond to LPS, and express intra-
ellular TLR4, although surface expression of TLR4 is probably
eak (Kanevskiy et al., 2013; Souza-Fonseca-Guimaraes et al.,
012). However, LPS treatment decreases NK cell degranulation
Kanevskiy et al., 2013), and injection of LPS into healthy volunteers
s associated with a marked decrease in NK cell numbers (Lauw
t al., 2000). Furthermore, we show that the percentage of GrM-
ositive NK cells in PBMCs does not change following LPS treatment
Fig. 2). This argues against a role for NK cells in granzyme secretion.
ther cell types that express GrM and GrK include NKT cells, 
 cells, and CD8+ T cells (Bovenschen and Kummer, 2010). These
ytotoxic lymphocytes may  also contribute to granzyme release
pon LPS or bacterial stimulation, although the percentage of GrM-
ositive NKT cells and CD8+ T cells in PBMCs do not change upon
PS treatment (Fig. 2). GrB expression has been found in a number
f cell types other than cytotoxic lymphocytes, including dendritic
ells, mast cells, basophils, and B cells (Hagn and Jahrsdorfer, 2012),
nd it is possible that these cell types also express GrM and/or GrK.
nterestingly, our data show – for the ﬁrst time – that GrM also is
xpressed by monocytes and that its expression increases in CD16+
onocytes upon LPS stimulation (Fig. 2). Whether or not the latter
ells also contribute to the release of GrM requires further study.
inally, we cannot fully exclude the possibility that other (non-
ematopoietic) cells may  contribute to granzyme release in vivo,
hich may  explain the absence of GrK release in vitro while it is
etected in vivo (Fig. 2).
How LPS and gram-negative bacteria cause granzyme release
emains to be elucidated. Lauw et al. (2000) showed that release of
rA and GrB in response to the gram-negative bacterium Burkholde-
ia pseudomallei in whole blood cultures is inhibited by adding
eutralizing monoclonal antibodies to TNF or IL-12 (Lauw et al.,
000). This suggests that LPS-induced cytokines trigger cellular
ranzyme release. Since granzymes also induce cytokine release
Wensink et al., 2014; Metkar et al., 2008), a positive feedback loop
ay  enhance release of both granzymes and cytokines. Further
esearch is required to address this possibility.
Excessive cytokine production in response to LPS or gram-
egative bacteria can contribute to the development of severe
epsis (Angus and van der Poll, 2013). Currently, there are no ther-
pies available to modulate the immune response during sepsis,
nd the only treatment option is to administer antibiotics. One of
he major challenges in treating sepsis is to increase the patients’
hances of survival by dampening the immune response to the
athogen. Inhibition of granzymes expression or blocking proin-
ammatory granzyme functions may  contribute to this goal.logy 221 (2016) 773–777 777
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